Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 14 | 2026 | 227 | 1.440 |
Why?
|
| Immunologic Factors | 5 | 2014 | 110 | 0.890 |
Why?
|
| Demyelinating Diseases | 2 | 2014 | 15 | 0.750 |
Why?
|
| Neuromyelitis Optica | 2 | 2011 | 12 | 0.680 |
Why?
|
| Cervical Cord | 1 | 2020 | 5 | 0.660 |
Why?
|
| Spondylosis | 1 | 2020 | 26 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 58 | 0.600 |
Why?
|
| Papillomavirus Vaccines | 2 | 2010 | 69 | 0.590 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2026 | 2250 | 0.440 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2012 | 59 | 0.430 |
Why?
|
| Fumarates | 1 | 2014 | 10 | 0.420 |
Why?
|
| Psoriasis | 1 | 2014 | 59 | 0.400 |
Why?
|
| Interferons | 1 | 2014 | 74 | 0.400 |
Why?
|
| Interferon-beta | 2 | 2011 | 79 | 0.390 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 381 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2014 | 326 | 0.340 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2011 | 34 | 0.340 |
Why?
|
| Tremor | 1 | 2011 | 25 | 0.340 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 796 | 0.330 |
Why?
|
| Head | 1 | 2011 | 57 | 0.320 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2010 | 4 | 0.320 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 3 | 0.310 |
Why?
|
| Sarcoidosis | 1 | 2010 | 33 | 0.310 |
Why?
|
| Receptors, GABA | 2 | 2026 | 13 | 0.300 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2007 | 297 | 0.300 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 108 | 0.290 |
Why?
|
| Adult | 13 | 2026 | 17461 | 0.270 |
Why?
|
| Cognition Disorders | 1 | 2010 | 224 | 0.270 |
Why?
|
| Parkinson Disease | 1 | 2010 | 135 | 0.270 |
Why?
|
| Rituximab | 4 | 2014 | 89 | 0.270 |
Why?
|
| Vaccination | 1 | 2010 | 384 | 0.260 |
Why?
|
| Peptides | 1 | 2011 | 590 | 0.260 |
Why?
|
| Positron-Emission Tomography | 2 | 2026 | 231 | 0.250 |
Why?
|
| Skull | 1 | 2026 | 52 | 0.240 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2026 | 16 | 0.240 |
Why?
|
| Female | 19 | 2026 | 34193 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 875 | 0.230 |
Why?
|
| Genetic Heterogeneity | 1 | 2003 | 21 | 0.200 |
Why?
|
| Humans | 26 | 2026 | 65463 | 0.200 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2003 | 28 | 0.200 |
Why?
|
| Male | 15 | 2026 | 31187 | 0.190 |
Why?
|
| Middle Aged | 9 | 2026 | 18387 | 0.190 |
Why?
|
| Brain | 4 | 2026 | 1611 | 0.170 |
Why?
|
| Disease Progression | 3 | 2026 | 1223 | 0.160 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 563 | 0.150 |
Why?
|
| Spinal Cord | 1 | 2020 | 210 | 0.150 |
Why?
|
| Biomarkers | 2 | 2014 | 1481 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 1631 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2014 | 5806 | 0.130 |
Why?
|
| Natalizumab | 1 | 2016 | 11 | 0.120 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 18 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6929 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2020 | 2633 | 0.110 |
Why?
|
| Interleukin-10 | 2 | 2014 | 164 | 0.110 |
Why?
|
| Dimethyl Fumarate | 1 | 2014 | 8 | 0.110 |
Why?
|
| Myasthenia Gravis | 1 | 2014 | 12 | 0.100 |
Why?
|
| Recurrence | 2 | 2016 | 662 | 0.100 |
Why?
|
| Twins | 2 | 2006 | 52 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2003 | 3155 | 0.100 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 4 | 0.090 |
Why?
|
| Glatiramer Acetate | 1 | 2011 | 8 | 0.090 |
Why?
|
| Genetic Linkage | 3 | 2003 | 97 | 0.090 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 64 | 0.090 |
Why?
|
| Antibodies | 1 | 2012 | 187 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2011 | 93 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 81 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 160 | 0.080 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2010 | 7 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 220 | 0.080 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2010 | 2 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 449 | 0.080 |
Why?
|
| Risk Factors | 1 | 2020 | 5458 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 185 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2012 | 200 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2010 | 139 | 0.080 |
Why?
|
| RNA | 1 | 2013 | 426 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2010 | 140 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 466 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 3488 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 713 | 0.060 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 14 | 0.060 |
Why?
|
| Italy | 5 | 2006 | 69 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2003 | 129 | 0.060 |
Why?
|
| Pyridines | 1 | 2026 | 120 | 0.060 |
Why?
|
| Carbon Radioisotopes | 1 | 2024 | 12 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 787 | 0.050 |
Why?
|
| Aged | 1 | 2020 | 15052 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 144 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2003 | 47 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2003 | 1143 | 0.050 |
Why?
|
| White Matter | 1 | 2024 | 128 | 0.050 |
Why?
|
| Receptors, Prolactin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 40 | 0.050 |
Why?
|
| Pedigree | 1 | 2003 | 193 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3774 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2003 | 142 | 0.050 |
Why?
|
| Genome, Human | 1 | 2003 | 237 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2003 | 183 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2003 | 1008 | 0.040 |
Why?
|
| Mice | 2 | 2012 | 11138 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 239 | 0.040 |
Why?
|
| Base Sequence | 1 | 2003 | 1331 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1233 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2000 | 17 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 512 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1979 | 0.040 |
Why?
|
| Family Health | 1 | 2000 | 68 | 0.040 |
Why?
|
| Adolescent | 1 | 2010 | 6332 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 5644 | 0.040 |
Why?
|
| Myelin Basic Protein | 1 | 1999 | 20 | 0.040 |
Why?
|
| Animals | 3 | 2013 | 21381 | 0.040 |
Why?
|
| Immune System | 1 | 2000 | 132 | 0.040 |
Why?
|
| Antigens | 1 | 1999 | 145 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 178 | 0.030 |
Why?
|
| Epitopes | 1 | 1999 | 291 | 0.030 |
Why?
|
| Inflammation | 1 | 2024 | 1193 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1999 | 281 | 0.030 |
Why?
|
| Alleles | 3 | 2003 | 454 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2006 | 734 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 296 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2012 | 417 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2016 | 165 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2003 | 124 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2492 | 0.020 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2012 | 9 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 42 | 0.020 |
Why?
|
| Genotype | 2 | 2003 | 674 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 312 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 247 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 324 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 518 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 342 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2012 | 189 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 663 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 482 | 0.020 |
Why?
|
| Interferon beta-1a | 1 | 2007 | 9 | 0.020 |
Why?
|
| Filamins | 1 | 2007 | 8 | 0.020 |
Why?
|
| Contractile Proteins | 1 | 2007 | 14 | 0.020 |
Why?
|
| Interleukin-16 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3324 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2007 | 81 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 115 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2013 | 707 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 169 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 498 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2305 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 380 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4837 | 0.010 |
Why?
|
| International Cooperation | 1 | 2003 | 87 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2003 | 17 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2003 | 28 | 0.010 |
Why?
|
| Introns | 1 | 2003 | 114 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 238 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 208 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 513 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2000 | 16 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 26 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2000 | 32 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1999 | 112 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2776 | 0.010 |
Why?
|
| Cell Line | 1 | 1999 | 2024 | 0.010 |
Why?
|